Wounds and Injuries

All Conditions

Neoplasms

Rare Diseases

Sarcoma

Soft Tissue Neoplasms

Lipoma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Soft Tissue Sarcoma

After subcuticular skin suture, patients receive standard dressing with adhesive wound tapes.

After subcuticular skin suture, patients receive an incisional negative pressure dressing for 5 days.

A negative pressure dressing is applied to the skin incision.

Incisional negative pressure wound therapy

Regular adhesive wound tapes are applied over the closed skin.

Wound dressing with adhesive tapes

Björn Behr, MD

Mehran Dadras, MD

This study is aimed to examine the value of incisional negative pressure therapy after resection of soft tissue tumors. Its a prospective randomized trial comparing incisional negative pressure to standard wound dressings.

Wound healing after resection of large soft tissue tumors is often impaired by large dead space and fluid collection, potentially resulting in seroma formation and infection. Aim of the study is to compare negative pressure wound therapy to standard wound dressing in terms of quantity of drainage fluid and wound healing complications.

Incisional Negative Pressure Wound Therapy for Resection of Soft Tissue Tumors

Inzisionelle Negative Drucktherapie Nach Resektion Von Weichteiltumoren - Eine Prospektive, Randomisierte, Kontrollierte Klinische Studie

Measurement of total fluid amounts in drains and negative pressure device

Assessment of course of wound healing, necessary operative revisions, seroma formation

Ruhr University of Bochum

Consultant, Department of Plastic Surgery

Neoplasms, Adipose Tissue

This will utilize the traditional method of performance of regional block

In this arm, regional block will be performed under the ultrasound guidance

In the second arm, ultrasound will be used to guide the regional block

Ultrasound guidance

Tarek F. Tammam, Prof.

There is limited information on using the ultrasonography for block placement concerning lipoma excision. A new type of regional blockade, performed under ultrasound, can ensure proper block placement with accurate local anesthetics deposition. Investigators hypothesized that ultrasound guidance can reduce the number of needle passes to complete the block placement. Investigators will compare namely ultrasound guided regional blockade and traditional method regarding the number of needle passes to complete the block placement.

50 patients between the ages of 18 and 60 years with American Society of Anesthesiologists (ASA) physical status I-III, scheduled for superficial subcutaneous lipoma (sized from 5 to 7 cm) excision will be enrolled in prospective comparative randomized clinical study.

Patients will be randomized into two groups: U (n = 25), in whom regional blockade was performed using US-guidance; and C (n = 25), in whom regional block was performed using the traditional method. Patients will be randomly assigned on a one-to-one ratio. Randomization will be performed by means of a computer generated random-numbers table. Group allocation will be concealed in sealed opaque envelopes that will not opened until patient consent had been obtained.

All patients will be pre-medicated with oral diazepam (7.5 mg) 30 min before the procedure, and IV fentanyl (50 ug) will be administered 5 minutes before placement of the block. Before the procedure, an IV access and standard monitoring of electrocardiogram (ECG), noninvasive blood pressure (NIBP), and peripheral oxygen saturation (SPO2) will be established.

Primary outcome includes the number of needle attempts (number of skin punctures and needle redirections) needed to complete the block placement. It will be documented by an investigator blinded to the aim of the study. Patient demographics, duration of surgery, patient's ASA physical status and other study outcomes will be documented by independent investigators who were not involved in the block placement procedure and were blinded to the group assignment.

Ultra-sounded Guided Regional Blockade for Lipoma Excision

Ultrasound-Guided Regional Blockade for Lipoma Excision: a New Approach to an Old Technique

The block success rate is assessed according to the adequacy of surgical anesthesia and is defined as complete loss of sensation to pinprick within 20 min of anesthetic administration and if no supplementation (sedative or analgesic) is required during surgery.Partial block is defined as inadequate sensory blockade after 20 min of anesthetic administration. The supplementation (additional LA infiltration or IV analgesic; fentanyl) is required to complete the proposed surgery. Failed block is considered if general anesthesia is required to complete the proposed surgery.

Suez Canal University

Tarek F.Tammam, M.D., Ph.D, Department of Anesthesia and Intensive Care, Faculty of Medicine, Suez Canal University Hospital, Egypt

Gastrointestinal Agents

All Drugs and Chemicals

Deoxycholic Acid

Participants received 0.5% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.

Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.

Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.

Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.

Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.

Deoxycholic Acid Injection

Placebo

Stacy R. Smith, M.D.

The purpose of this research is to compare the safety and effectiveness of 4 different concentrations of deoxycholic acid injection against a placebo in the treatment of superficial lipomas.

A lipoma is a fatty lump typically located on the trunk, shoulder, arms or legs. For the purposes of this study, only lipomas on the trunk, arms, legs, or neck were treated. (Lipomas on the face, wrists, hands, lower portion of the spine, genitals, ankles, or feet were not treated.)

Deoxycholic Acid Injection for the Treatment of Superficial Lipomas

Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study of the Pharmacokinetics, Safety, and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Intralipomal Injections for the Treatment of Superficial Lipomas

Kythera Biopharmaceuticals

Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously

AA4500

placebo

Zachary E Gerut, MD

The purpose of this study is to determine whether collagenase is effective in reducing the surface area of a subcutaneous benign lipoma.

This study will evaluate the safety and efficacy of a Food and Drug Administration (FDA) approved drug (XIAFLEX) in the treatment of lipoma (fatty tumors). The fat in the lipoma is like normal fat except that it is enclosed in a balloon-like structure which is made of collagen (fibrous tissue). Treatment of the lipoma with an injection of XIAFLEX (a protein that breaks down collagen fibers) may dissolve the collagen/fibrous strands thereby decreasing the size of the lipoma or removing it. Each subject must have two lipomas; one lipoma to be treated with placebo and one lipoma to be treated with study drug, both to be observed similarly throughout the trial.

Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma

A Double Blind Study to Evaluate the Safety and Efficacy of Collagenase Clostridium Histolyticum (AA4500) in the Treatment of Lipoma

Visible surface area is defined as the longest dimension ("length") times the longest dimension perpendicular to length ("width"). Visible surface area will be analyzed as the percent change from baseline.

The primary efficacy outcome is lipoma visible surface area defined as the longest dimension ("length") times the longest dimension perpendicular to length ("width"). Visible surface area will be analyzed as the percent change from baseline at the 6-month visit.

The number of participants with at least 50% decrease in visible lipoma surface area of lipoma relative to baseline

Change from baseline in lipoma length Calculated as the percent change from baseline for length of the lipoma treated with AA4500 and the lipoma treated with placebo.

Subjects very satisfied or somewhat satisfied with study treatment based upon Subject Questionnaire

Advance Biofactures Corporation

Gerut, Zachary, M.D.

Treatment emergent adverse events were collected after the date of administration of study medication through the last visit at 6 months post administration.

single injection of 0.58 mg study drug

AA4500: Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously

single injection of placebo

placebo: Placebo

single injection of 0.58 mg study drug and placebo

Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously

AA4500 and Placebo

Age, Continuous

Gender

Race (NIH/OMB)

Dr. Zachary E. Gerut, Sponsor/Investigator

Each subject received a single injection of 1 mL containing 0.58 mg AA4500

Each subject received a single injection of 1 mL placebo

All 19 subjects enrolled with 2 lipomas. All received AA4500 in one lipoma and placebo in the other lipoma.

Percent Change From Baseline in Surface Area of the Lipoma at Six Months

Responder Analysis

Each participants received a single injection of 1 mL containing 0.58 mg AA4500

Each participant received a single injection of 1 mL placebo

Percent Change From Baseline in Greatest Dimension (Length) of Lipoma at 6 Months

1 participant did not complete the questionnaire at the final visit; therefore the analysis population was based upon 18 participants

Subject Satisfaction

Change in Visible Surface Area

Each subject received a single injection of 1 mL containing 0.58 mg AA4500 in one lipoma and a single injection of 1 mL placebo in another lipoma

Lipoma #1 was randomized to AA4500 or placebo with Lipoma #2 receiving the alternate intervention

Overall Study

Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.

Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.

Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.

Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.

Matching vehicle placebo administered via intralipomal injection.

Patricia S. Walker, M.D., Ph.D.

The purpose of this research is to compare the safety and effectiveness of 3 different concentrations of deoxycholic acid for injection against a placebo in the treatment of superficial lipomas.

A lipoma is a fatty lump typically located on the trunk, shoulder, arms, or legs. For the purposes of this study, only lipomas on the trunk, arms, legs, or neck were treated. (Lipomas on the face, wrists, hands, lower portion of the spine, genitals, ankles, or feet were not treated.)

Phase 2 Study for the Treatment of Superficial Lipomas

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Intralipomal Injections for the Treatment of Superficial Lipomas

Severity of AEs was determined using the following scale:

Mild: The participant was aware of a sign or symptom, but it was easily tolerated; Moderate: Discomfort or interference with usual activity; Severe: Incapacitating, with inability to engage in usual activity. The investigator determined the relationship of each AE to the administration of study material by answering the question: "Was there a reasonable possibility that the event may have been caused by treatment with study material?" A serious AE was an event that constituted a significant medical hazard or side effect, regardless of the investigator's or sponsor's opinion regarding relatedness to study material. Serious AEs included any event that was fatal or life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or other significant medical hazard.

An abnormality is defined as a value outside the limits of the expanded normal range/notable range.

A needle core tissue sample biopsy was performed at screening for all treated lipomas.

After the completion of all tests and procedures scheduled for week 20, participants with treated lipomas that remained palpable could have their treated lipomas excised.

At randomization 1 to 3 lipomas were selected for treatment. Lipomas were measured in 3 dimensions (longest length, perpendicular width, and height if possible) using digital calipers.

Complete clearance indicates target lipoma(s) not present or detectable, and ≥ 75% clearance is defined as a ≥ 75% reduction from baseline in the area of target lipoma(s).

For participants with \> 1 target lipoma, the total area of all target lipomas was used in the calculation of response.

Percent change from baseline was calculated as the baseline total lipoma area - postbaseline total lipoma area / baseline total lipoma area \* 100. A positive change indicates a reduction in size.

Deoxycholic Acid 1%

Deoxycholic Acid 2%

Deoxycholic Acid 4%

Participants received matching placebo administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.

Total

Sex: Female, Male

Modified intent-to-treat (MITT) population included all randomized participants who had received at least 1 dose of study material and who had at least 1 postbaseline observation.

Clinical Trial Disclosure

Any adverse event

Any treatment-related adverse event

Any serious adverse event

Any severe adverse event

Any adverse event leading to drug discontinuation

Safety population (all participants who received at least 1 dose of study medication)

Number of Participants With Adverse Events (AEs)

Complete Clearance

≥ 75% Cleared

Percentage of Participants With Complete Clearance or ≥ 75% Clearance

Blood triglycerides

Alanine transaminase

Aspartate aminotransferase

Alkaline phosphatase

Urinalysis - Glucose

Number of Participants With Newly Occurring or Worsening Biochemistry/Hematology/Urinalysis Abnormalities

Week 12

Week 16

Week 20

Percent Change From Baseline in the Sum of the Areas of All Treated Lipomas

Number of Participants With Clinically Significant Changes in Vital Signs or Weight

Acute inflammation

Chronic inflammation

Fibrosis/scarring

Hemorrhage

Mature adipose tissue

Necrosis

Safety population with biopsy results at screening

Number of Participants With Positive Histopathology Results at Screening

Safety population with biopsy results at week 20

Number of Participants With Positive Histopathology Results at Week 20

Skin and Connective Tissue Diseases

Nutritional and Metabolic Diseases

Lipomatosis

Lipomatosis, Multiple Symmetrical

Skin Diseases

Metabolic Diseases

Lipid Metabolism Disorders

Multiple Symmetric Lipomatosis

Anti-Inflammatory Agents

Hydrocortisone

Hydrocortisone 17-butyrate 21-propionate

Hydrocortisone acetate

Hydrocortisone hemisuccinate

Hydrocortisone (20 mg/day) in a 10-5-5 schedule: 10 mg at 0700h, 5 mg at 1200h, and 5 mg at 1700h. The hydrocortisone periods last 10 weeks per period. In total, there are two hydrocortisone periods.

Placebo (20 mg/day) in a 10-5-5 schedule: 10 mg at 0700h, 5 mg at 1200h, and 5 mg at 1700h. The placebo periods last 10 weeks per period. In total, there are two placebo periods.

Laura de Graaff, MD, PhD

A young women with Symmetric Lipomatosis associated with Neuropathy (SLN) was seen at the department of Internal Medicine - Endocrinology and at the department of Neurology at the Erasmus MC, Rotterdam, the Netherlands. The patient presented with balance problems due to neuropathy and prominent cervical and genital lipomas. In the past, the patient had been treated with steroids for a short period. The patient noticed that, as a 'side effect', during this treatment period the lipomas shrank and that the balance problems nearly disappeared. The complaints reappeared after withdrawal of the steroids. In the current study, the usefulness of steroid treatment in this single patient will be investigated in an N-of-1 trial.

Primary objective: to determine the efficacy of hydrocortisone treatment for neuropathy on an individual level in a patient with SLN as assessed with the Rasch-built Overall Disability Scale (RODS).

A young women with Symmetric Lipomatosis associated with Neuropathy (SLN) was seen at the department of Internal Medicine-Endocrinology and the department of Neurology at the Erasmus MC, Rotterdam, the Netherlands. SLN is a rare disorder characterized by symmetric lipomas and neuropathy due to a homozygous mutation of c.2119C\>T p.R707W in the MFN2 gene. Only seven cases of SLN are known in the literature. The patient presented with balance problems due to neuropathy and prominent cervical and genital lipomas. In the past, the patient had been treated with steroids (prednisolone) for a short period, because of a suspicion of adrenal insufficiency. The patient noticed that, as a 'side effect', during this treatment period the lipomas shrank and that the balance problems nearly disappeared. However, as a synacthen test showed that adrenal function was normal, steroid treatment was tapered and the complaints reappeared. In a follow-up visit at our outpatient clinic, the patient requested to be treated again with steroids for the complaints. As there is no literature on the effects of treatment with steroids on balance problems and on the size of lipomas in patients with SLN, the usefulness of steroid treatment in this single patient is investigated in an N-of-1 trial in order to improve the clinical care for this patient.

Primary objective: to determine the efficacy of hydrocortisone treatment for neuropathy on an individual level in a patient with SLN as assessed with the Rasch-built Overall Disability Scale (RODS).

Secondary objectives: to determine the effect of hydrocortisone treatment on the size of a lipoma in the neck, on the Medical Research Council (MRC) sum score and on specific personalized goals that are important to the patient and the patients' environment (Goal Attainment Scaling (GAS)).

An N-of-1 study is considered as a reliable and suitable design to assess the efficacy of a treatment at an individual level. The study will consist of two cycles with each two periods of active treatment or placebo, a run-in period, tapering period and a wash-out period. Within each cycle, the sequence of the hydrocortisone and placebo period is randomized.

Both the participant and the investigator are masked. The investigator is also the care provider and outcomes assessor. The statistician and clinical pharmacist are unblinded.

Hydrocortisone Treatment for Symmetric Lipomatosis Associated With Neuropathy (SLN): an N-of-1 Study Hydrocortisone Treatment for Symmetric Lipomatosis Associated With Neuropathy (SLN): an N-of-1 Study

Hydrocortisone Treatment for Symmetric Lipomatosis Associated With Neuropathy (SLN): an N-of-1 Study

Individual participant data is available upon reasonable request.

The RODS is a validated 24-items questionnaire to measure the activity and social participation limitations in patients with neuropathy. The questionnaire has a score range of 0 to 100. A higher score means a better outcome (less limitations of the neuropathy)

The size of the lipoma will be measured with a centimeter by the researcher during hospital visits. The researcher will also take a picture of the lipoma in front of graph paper in a standardized manner. In between hospital visits, the participant will take a picture of the lipoma in front of graph paper.

The MRC sumscore is a validated tool to measure muscle strength and must be carried out by a physician, nurse, physiotherapist or other professional. The score has a range of 1 to 5. A higher score means a better outcome.

GAS is an individualized outcome measure in which several personal goals and the corresponding scaling are defined in consultation with the patient. The scaling is standardized, which makes it possible to reliably measure the change in the situation of the patient. The levels range from -3 to +2. A higher level means a better outcome. The predefined personal goals are a measure of the effectivity of the treatment. If possible, three goals will be set.

Erasmus Medical Center

Principal investigator

single injection 0.058 mg Collagenase Clostridium Histolyticum

single injection 0.15 mg Collagenase Clostridium Histolyticum

single injection 0.29 mg Collagenase Clostridium Histolyticum

single injection 0.44 mg Collagenase Clostridium Histolyticum

This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.

Collagenase Clostridium Histolyticum

Zachary E Gerut, M.D.

The purpose of this research is to evaluate the safest and most effective dose of a Food and Drug Administration (FDA) approved drug (XIAFLEX) in the treatment of lipoma (fatty tumors of varying sizes that occur commonly in the adult population). The fat in the lipoma is like normal fat except that it is enclosed in a balloon-like structure which is made of collagen (fibrous tissue). Treatment of the lipoma with an injection of XIAFLEX (a protein that breaks down collagen fibers) may dissolve the collagen/fibrous strands thereby decreasing the size of the lipoma or removing it.

Lipomas are common mesenchymal, benign, fatty tumors of varying sizes that occur in the general adult population. They usually present as painful or annoying lumps that are palpable and often visible in the subcutaneous tissue. Many subcutaneous lipomas are asymptomatic and are removed for non-medical reasons. However, they may cause the subject pain or discomfort or interfere with normal activity.

Spontaneous remission of lipomas has not been reported. A lipoma, once it presents itself, remains there for the lifetime of a person who carries it and may stay small or become larger. Alternative treatments of the lipoma are surgery or liposuction. If a large excision is performed there is the problem of having a very large scar and the accompanying issues of healing a large scar, or possible formation of a hematoma followed by consolidation of the hematoma and the remnants of a mass of scar tissue. This is often painful and more problematic than the original lipoma. liposuction also has the potential for hematoma formation followed by scar mass residual.

To avoid the complications listed above, a non-invasive method of treatment, such as enzyme mediated disassociation of adipose tissue, would be desirable. The primary aim of this study is to perform a step-wise approach in dosing to evaluate the safety and efficacy of clostridium histolyticum as a non-operative treatment for lipoma.

A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma

The primary efficacy outcome is the visible surface area of the lipoma measured as the longest dimension (length) times the longest dimension perpendicular to length (width). Visible surface area will be determined by caliper and will be analyzed as the percent change from baseline at the 6-month post injection visit.

A secondary outcome is the relative change in volume of the lipoma as determined by MRI. This outcome will be analyzed as the change from baseline to 6 months post injection.

Zachary Gerut

Sponsor-Investigator

single injection 0.058 mg Collagenase Clostridium Histolyticum

Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.

Dose #1

single injection 0.15 mg Collagenase Clostridium Histolyticum

Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.

Dose #2

single injection 0.29 mg Collagenase Clostridium Histolyticum

Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.

Dose #3

single injection 0.44 mg Collagenase Clostridium Histolyticum

Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Incisional Negative Pressure Wound Therapy for Resection of Soft Tissue Tumors	NCT03900078	Soft Tissue Sar... Lipoma Tumor	Incisional nega... Wound dressing ...	18 Years -	Ruhr University of Bochum
Ultra-sounded Guided Regional Blockade for Lipoma Excision	NCT02753361	Lipomas	Ultrasound guid...	18 Years - 60 Years	Suez Canal University
Deoxycholic Acid Injection for the Treatment of Superficial Lipomas	NCT00422188	Lipoma	Deoxycholic Aci... Placebo	18 Years - 65 Years	Kythera Biopharmaceuticals
Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma	NCT02249052	Lipoma	AA4500 placebo	18 Years - 75 Years	Gerut, Zachary, M.D.
Phase 2 Study for the Treatment of Superficial Lipomas	NCT00608842	Lipoma	Deoxycholic Aci... Placebo	18 Years - 65 Years	Kythera Biopharmaceuticals
Hydrocortisone Treatment for Symmetric Lipomatosis Associated With Neuropathy (SLN): an N-of-1 Study Hydrocortisone Treatment for Symmetric Lipomatosis Associated With Neuropathy (SLN): an N-of-1 Study	NCT04821583	Symmetric Lipom...	Hydrocortisone Placebo	31 Years -	Erasmus Medical Center
A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma	NCT01613313	Lipoma	Collagenase Clo...	18 Years - 75 Years	Gerut, Zachary, M.D.
Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas	NCT00624416	Lipoma	Prednisolone sy...	18 Years - 60 Years	Pennington Biomedical Research Center
Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas	NCT00624416	Lipoma	Prednisolone sy...	18 Years - 60 Years	Pennington Biomedical Research Center
A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma	NCT01613313	Lipoma	Collagenase Clo...	18 Years - 75 Years	Gerut, Zachary, M.D.
Hydrocortisone Treatment for Symmetric Lipomatosis Associated With Neuropathy (SLN): an N-of-1 Study Hydrocortisone Treatment for Symmetric Lipomatosis Associated With Neuropathy (SLN): an N-of-1 Study	NCT04821583	Symmetric Lipom...	Hydrocortisone Placebo	31 Years -	Erasmus Medical Center
Survey of Optical Values of the Breast Using Radiation-Free Pressure-Free Optical Scanning	NCT00671385	Breast Lesions Breast Cyst Early-Stage Bre... Benign Growth, ...		21 Years - 50 Years	Spectros Corporation

Spots Global Cancer Trial Database for lipoma

Every month we try and update this database with for lipoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for lipoma

Every month we try and update this database with for lipoma cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for lipoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.